F3 Platform Biologics

F3 Platform Biologics is a late-stage biopharmaceutical company dedicated to the development and commercialization of novel, practical human biotechnologies. F3 Platform Biologics focuses on the research, clinical development, and eventual commercialization of new indications surrounding Amifostine, a compound previously approved by the FDA for indications involving the prevention and treatment of side effects associated with cancer therapy and radiation therapy.